|
Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices
FiercePharma Nomura Holdings identified the Cephalon ($CEPH) wakefulness drug Provigil, with $1.1 billion in US sales in 2010; the Takeda Pharmaceuticals ($TKPHF) diabetes pill Actos, with $3.35 billion; and the Novartis ($NVS) blood-pressure remedy Diovan, … |
 Hindu Business Line |
Ranbaxy: The long and winding road to salvation
Hindu Business Line … 2010 (off patent in September 2012), the sleep disorder drug Provigil, which has a $1.1-billion sales in 2010 and AstraZeneca's heart-burn treatment drug Nexium that had an annual sales of $5.2 billion in 2010 (expected to be launched in May 2014). Sell Ranbaxy Labs; target of Rs 355: PINC ResearchMoneycontrol.com all 139 news articles » |
 Queen’s Journal |
Queen's student Joseph Gabriel mixes hip hop with medicine
Queen’s Journal “Scrip rocks folks 'cause they need it/ when I jot notes on the pad don't be mad if you can't read it/ or compete or hover close to being half as ill/ 'cause my lines open eyes like a double dose of modafinil,” he said, sampling some of his latest … |
 Bloomberg |
Ranbaxy Falls Most Since March on Proposed Settlement Costs: Mumbai Mover
Bloomberg Provigil, Diovan Near-term exclusivities relate to versions of the sleep- disorder drug Provigil, which had $1.1 billion in sales in 2010; Actos; and Diovan, a blood-pressure pill made by Novartis AG (NOVN) that generated $1.5 billion in annual sales, … Share market, analysts give Ranbaxy a thumbs downBusiness Standard Ranbaxy falls 7% to nine-month low on USFDA settlement costsEconomic Times Tough US strictures on RanbaxyCalcutta Telegraph Times of India -Hindu Business Line all 154 news articles » |